AstraZeneca’s GLP-1 Pill Heads To Late-Stage Trials

AstraZeneca Plc (NASDAQ:AZN) is advancing its oral GLP-1 receptor agonist, elecoglipron, into an extensive Phase 3 development program after the drug delivered significant weight-loss and diabetes-control results in two Phase 2b studies. The findings, presented at the...